Agios Pharmaceuticals (AGIO) to Post Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is anticipated to post its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Agios Pharmaceuticals to post earnings of ($1.6588) per share and revenue of $26.0650 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:00 AM ET.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, topping analysts’ consensus estimates of ($1.81) by $0.12. The company had revenue of $20.75 million for the quarter, compared to analyst estimates of $13.30 million. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The business’s revenue for the quarter was up 137.7% on a year-over-year basis. On average, analysts expect Agios Pharmaceuticals to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Agios Pharmaceuticals Stock Down 3.5%

NASDAQ AGIO opened at $36.05 on Thursday. The company has a market capitalization of $2.14 billion, a price-to-earnings ratio of -4.97 and a beta of 0.54. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00. The stock has a fifty day simple moving average of $33.58 and a 200 day simple moving average of $30.56.

Institutional Trading of Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of AGIO. T. Rowe Price Investment Management Inc. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at $25,000. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals in the 1st quarter valued at about $40,000. Caitong International Asset Management Co. Ltd acquired a new position in Agios Pharmaceuticals during the 4th quarter valued at about $49,000. Quantbot Technologies LP bought a new stake in Agios Pharmaceuticals during the 3rd quarter worth approximately $79,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the first quarter worth approximately $133,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. decreased their price target on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a research note on Thursday, June 11th. Bank of America boosted their price target on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. HC Wainwright decreased their price objective on shares of Agios Pharmaceuticals from $54.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday. Royal Bank Of Canada boosted their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Wednesday, June 24th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $42.78.

Key Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Negative Sentiment: Agios scrapped the tebapivat sickle cell disease program after Phase 2 data failed to show a compelling benefit versus existing options, a setback that weakens a key pipeline opportunity. Article Title
• Negative Sentiment: Multiple reports highlighted the stock’s decline following the decision, with coverage emphasizing that the company is abandoning the sickle cell candidate after lackluster trial results. Article Title
• Negative Sentiment: Investor sentiment is also being dampened by the loss of a potential growth driver in sickle cell disease, even though Agios’ other PK activator, mitapivat, remains under FDA Priority Review with a PDUFA date of November 1, 2026. Article Title

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.